Abstract

Stress is linked to the central nervous system. In addition to its primary function in the body, it also assists in body upkeep. As a result, its proper operation is critical for both health and sickness. When the central nervous system is out of equilibrium, the CNS system's mechanism changes. Understanding the mechanism of stress is crucial for developing pharmaceutical methods for its prevention. Among the common molecular pathways contributing to impaired brain function are inflammation, immunomodulation and oxidative stress. A variety of drugs and chemicals are used to experimentally induce stress of CNS, which are assessed in the laboratory by physiological, physically, emotionally and pathological biomarkers. The present review outlines some of the fundamental ideas in stress, as well as several preclinical screening methodologies and diagnostic markers.

Keywords: Stress; Brain; Markers; Diseases

References

1. Chauhan NS., et al. “Studies on antistress activity of Curculigo Orchioides gaertn”. Biomedical and Biotechnology Research Journal 5 (2021): 145-148.
2. Selye H. “The stress of life”. Mc Graw Hill Books, New York 1950 (2007): 1-11.
3. Synle S. “Guide to stress research”. Von Nostrand, New York (1976): 22-27.
4. Meera S and Chowdary GN. “Antistress And Immunomodulatory Activity of Aqueous Extract of Momordica charantia”. Pharmacognosy Magazine 19 (2009): 69-73.
5. Meaney MJ and Szyf M. “Environmental programming of stress responses through DNA methylation: life at the interface between a dynamic environment and a fixed genome”. Dialogues in Clinical Neuroscience 7 (2005): 103-123.
6. Hunter RG., et al. “Stress and the dynamic genome: Steroids, epigenetics, and the transposome”. Proceedings of the National Academy of Sciences of the United States of America (2014).
7. Bruce SM., et al. “Mechanisms of stress in the brain”. Nature Neuroscience 10 (2015): 1353-1363.
8. Hill MN and McEwen BS. “Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids”. Progress in Neuro-Psychopharmacology and Biological Psychiatry (2009).
9. Szyf M., et al. “Maternal programming of steroid receptor expression and phenotype through DNA methylation in the rat”. Frontiers in Neuroendocrinology 26 (2005): 139-162.
10. McGowan PO., et al. “Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse”. Nature Neuroscience 12 (2009): 241-243.
11. Rao RP., et al. “Glucocorticoids protect against the delayed behavioral and cellular effects of acute stress on the amygdala”. Biological Psychiatry 72 (2012): 466-475.
12. Zohar J., et al. “High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: interplay between clinical and animal studies”. European Neuropsychopharmacology 21 (2011): 796- 809.
13. Schelling G., et al. “Can posttraumatic stress disorder be prevented with glucocorticoids?” Annals of the New York Academy of Sciences 1032 (2004): 158-166.
14. Mitra R and Sapolsky RM. “Acute corticosterone treatment is sufficient to induce anxiety and amygdaloid dendritic hypertrophy”. Proceedings of the National Academy of Sciences of the United States of America 105 (2008): 5573-5578.
15. Pawlak R., et al. “Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus”. Proceedings of the National Academy of Sciences of the United States of America 102 (2005): 18201-18206.
16. Chen Y., et al. “Cellular and molecular mechanisms of hippocampal activation by acute stress are age-dependent”. Molecular Psychiatry 11 (2006): 992-1002.
17. Bennur S., et al. “Stress-induced spine loss in the medial amygdala is mediated by tissue plasminogen activator”. Neuroscience 144 (2007): 8-16.
18. Matys T., et al. “Tissue plasminogen activator promotes the effects of corticotropin releasing factor on the amygdala and anxiety-like behavior”. Proceedings of the National Academy of Sciences of the United States of America 101 (2004): 16345-16350.
19. Mucha M., et al. “Lipocalin-2 controls neuronal excitability and anxiety by regulating dendritic spine formation and maturation”. Proceedings of the National Academy of Sciences of the United States of America 108 (2011): 18436-18441.
20. Skrzypiec AE., et al. “Stress-induced lipocalin-2 controls dendritic spine formation and neuronal activity in the amygdala”. PLoS One 8 (2013): e61046.
21. File SE. “Factors controlling measures of anxiety and responses to novelty in the mouse”. Behavioural Brain Research 125 (2001): 151-157.
22. Blanchard DC., et al. “The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic”. European Journal of Pharmacology 463 (2003): 97-116.
23. Wood GE., et al. “Acute and chronic restraint stress alter the incidence of social conflict in male rats”. Hormones and Behavior 43 (2003): 205-213.
24. Sanchez C. “Stress-induced vocalisation in adult animals. A valid model of anxiety”. European Journal of Pharmacology 463 (2003): 133-143.
25. Hofer MA. “Multiple regulators of ultrasonic vocalization in the infant rat”. Psychoneuroendocrinology 21 (1996): 203-217.
26. Conrad CD., et al. “Support for a bimodal role for type II adrenal steroid receptors in spatial memory”. Neurobiology of Learning and Memory 72 (1999): 39-46.
27. Sgoifo A., et al. “Effects of sleep deprivation on cardiac autonomic and pituitary-adrenocortical stress reactivity in rats”. Psychoneuroendocrinology 31 (2006): 197-208.
28. Amit Z and Galina ZH. “Stress-induced analgesia: adaptive pain suppression”. Physiological Reviews 66 (1986): 1091-1120.
29. Olivier B., et al. “Stress-induced hyperthermia and anxiety: pharmacological validation”. European Journal of Pharmacology 463 (2003): 117-132.
30. Corwin RL and Buda-Levin A. “Behavioral models of binge-type eating”. Physiology and Behavior 82 (2004): 123-130.
31. Vladimir KP and Alexandre VP. “Experimental models of stress”. Dialogues in Clinical Neuroscience 8 (2006): 417-432.
32. Josko J. “Liberation of thyreotropin, thyroxine and triiodothyronine in the controllable and uncontrollable stress and after administration of naloxone in rats”. The Indian Journal of Physiology and Pharmacology 47 (1996): 303-310.
33. Van de Kar LD and Blair ML. “Forebrain pathways mediating stress-induced hormone secretion”. Frontiers in Neuroendocrinology 20 (1999): 1-48.
34. Jung ME., et al. “The discriminative stimulus effects of pentylenetetrazol as a model of anxiety: recent developments”. Neuroscience and Biobehavioral Reviews 26 (2002): 429-439.
35. Pechnick RN. “Effects of opioids on the hypothalamo-pituitary-adrenal axis”. Annual Review of Pharmacology and Toxicology 33 (1993): 353-382.
36. Skaper SD and Giusti LFP. “Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review”. CNS and Neurological Disorders (2014): 1654-1666.
37. Zafar T. “Potential biomarkers of emotional stress induced neurodegeneration”. Neurological Sciences 21 (2020): 100292.
38. Audet MC., et al. “Social defeat promotes specific cytokine variations within the prefrontal cortex upon subsequent aggressive or endotoxin challenges”. Brain, Behavior, and Immunity 25 (2001): 1197-1205.
39. Simpson RJ., et al. “Interleukin-6: structure-function relationships”. Protein Science 6 (1997): 929-955.
40. Hodes GE., et al. “Integrating Interleukin-6 into depression diagnosis and treatment”. Neurobiology of Stress 4 (2016): 15-22.
41. Pollak Y and Yirmiya R. “Cytokine-induced changes in mood and behaviour: implications for ‘depression due to a general medical condition’, immunotherapy and antidepressive treatment”. The International Journal of Neuropsychopharmacology 5 (2002): 389-399.
42. Fiedorowicz JG., et al. “Peripheral inflammation during abnormal mood states in bipolar I disorder”. Journal of Affective Disorders 187 (2015): 172-178.
43. Feyissa AM., et al. “Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression”. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33 (2009): 70-75.
44. Kirschbaum C and Hellhammer DH. “Salivary cortisol in psychoneuroendocrine research: recent developments and applications”. Psychoneuroendocrinology 19 (1995): 313-333.
45. Hoifodt RS., et al. “Cortisol levels and cognitive profile in major depression: a comparison of currently and previously depressed patients”. Psychoneuroendocrinology 99 (2009): 57-65.
46. Aydemir O and Deveci A. “BDNF measurement in stress-related mood disorders: a review of clinical studies”. Turkish Journal of Psychiatry 20 (2009): 385-391.
47. Liu T., et al. “A meta-analysis of oxidative stress markers in depression”. PLoS One 10 (2015): e0138904.
48. Vaidya AD. “Asian medicine-A global blessing. In: Indian Association of Studies in Traditional Asian Medicine (IASTAM) Silver Jubilee Convention Commemorative Volume”. International Journal of PharmTech Research (2005): 821-827.
49. Mashelkar RA. “India’s R and D: Reaching for the top”. Science 307 (2005): 1415-1417.
50. Gloth FM., et al. “Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder”. The Journal of Nutrition, Health and Aging 3 (1999): 5-7.
51. Walf AA and Frye CA. “A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior”. Neuropsychopharmacology 31 (2006): 1097-1111.
52. Jorge RE., et al. “Influence of major depression on 1 year outcome in patients with traumatic brain injury”. Journal of Neurosurgery 81 (1994): 723-726.
53. Bynum WF., et al. “Diagnostic and Statistical Manual of Mental Disorders: DSM IV. 4th edition”. Washington, DC: Psychiatric Epidemiology, American Psychiatric Association 4 (1994): 432-436.
54. López Rubalcava C., et al. “Anxiolytic like actions of the hexane extract from leaves of Annonacherimolia in two anxiety paradigms: Possible involvement of the GABA/benzodiazepine receptor complex”. Life Sciences 78 (2006): 730-737.
55. Carvalho Freitas MI and Costa M. “Anxiolytic and sedative effects of extracts and essential oil from Citrus aurantium L”. Biological and Pharmaceutical Bulletin 25 (2002): 1629-1633.
56. Amos S., et al. “Central inhibitory activity of the aqueous extract of Crinum giganteum”. Fitoterapia 74 (2003): 23-28.
57. Martínez AL., et al. “Neuropharmacological effects of an ethanol extract of the Magnolia dealbata Zucc. leaves in mice”. Journal of Ethnopharmacology 106 (2006): 250-255.